BM­S' con­fir­ma­to­ry tri­al of Kraza­ti hits pri­ma­ry end­point fol­low­ing 2022 ac­cel­er­at­ed ap­proval

Bris­tol My­ers Squibb scored a con­fir­ma­to­ry tri­al win for Kraza­ti, the KRAS in­hibitor it picked up ear­li­er this year through its $4.8 bil­lion ac­qui­si­tion of Mi­rati.

In De­cem­ber 2022, Kraza­ti won an ac­cel­er­at­ed ap­proval for non-small cell lung can­cer pa­tients, be­com­ing the sec­ond ap­proved KRAS in­hibitor in the US be­hind Am­gen’s Lumakras. Both drugs tar­get a mu­ta­tion called G12C in the hopes of halt­ing un­con­trolled ma­lig­nant cell growth.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER